Zebularine suppresses the apoptotic potential of 5-fluorouracil via cAMP/PKA/CREB pathway against human oral squamous cell carcinoma cells

Cancer Chemother Pharmacol. 2009 Jul;64(2):223-32. doi: 10.1007/s00280-008-0833-4. Epub 2008 Oct 2.

Abstract

Purpose: During tumorigenesis, tumor suppressor and tumor-related genes are commonly silenced by aberrant DNA methylation in their promoter regions, which is one of the important determinants of susceptibility to 5-fluorouracil (5-FU) in oral squamous cell carcinoma (OSCC) cells. Here, we examine the chemotherapeutic efficacy of epigenetic agents on 5-FU cytotoxicity.

Method: We investigated the effect of a DNA methyltransferase (DNMT) inhibitor, zebularine (Zeb), on the chemosensitivity of 5-FU and cisplatin (CDDP) by MTT and TUNEL methods, and compared the molecular mechanism of action with those of a GSK3beta inhibitor, LiCl, and an Hsp90 inhibitor, 17-AAG.

Results: A significant apoptotic effect by a combination of Zeb or 17-AAG was found in CDDP treatment; however, considerable suppression of 5-FU-induced apoptosis was observed after incubation with Zeb, 17-AAG, or LiCl. Zeb's suppressive effects were associated with activation of the cAMP/PKA/CREB pathway, differing from mechanisms of 17-AAG and LiCl. Suppression of 5-FU-induced apoptosis by Zeb was not associated with increased Bcl-2 and Bcl-xL expressions dependent on transcription factor CREB, and with the expression level of thymidylate synthase.

Conclusions: In the present study, we identified a more detailed mechanism of action by which Zeb suppresses 5-FU-induced apoptosis. These results indicate that combination therapies have to be carefully investigated due to potential harmful effects in the clinical application of DNMT inhibitors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / pharmacology
  • Antimetabolites, Antineoplastic / pharmacology
  • Antineoplastic Agents / pharmacology
  • Apoptosis / drug effects*
  • Benzoquinones / pharmacology
  • Blotting, Western
  • Carcinoma, Squamous Cell / drug therapy
  • Carcinoma, Squamous Cell / metabolism
  • Carcinoma, Squamous Cell / pathology
  • Cell Line, Tumor
  • Cisplatin / pharmacology
  • Cyclic AMP Response Element-Binding Protein / antagonists & inhibitors
  • Cyclic AMP Response Element-Binding Protein / metabolism*
  • Cyclic AMP-Dependent Protein Kinases / antagonists & inhibitors
  • Cyclic AMP-Dependent Protein Kinases / metabolism*
  • Cytidine / analogs & derivatives*
  • Cytidine / pharmacology
  • DNA (Cytosine-5-)-Methyltransferases / antagonists & inhibitors
  • Fluorouracil / antagonists & inhibitors*
  • Fluorouracil / pharmacology
  • Glycogen Synthase Kinase 3 / antagonists & inhibitors
  • Glycogen Synthase Kinase 3 / metabolism
  • Glycogen Synthase Kinase 3 beta
  • HSP90 Heat-Shock Proteins / antagonists & inhibitors
  • HSP90 Heat-Shock Proteins / metabolism
  • Humans
  • In Situ Nick-End Labeling
  • Lactams, Macrocyclic / pharmacology
  • Lithium Chloride / pharmacology
  • Mouth Neoplasms / drug therapy*
  • Mouth Neoplasms / metabolism
  • Mouth Neoplasms / pathology
  • NF-kappa B / metabolism
  • Phosphorylation / drug effects
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • Signal Transduction / drug effects

Substances

  • Adjuvants, Immunologic
  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents
  • Benzoquinones
  • CREB1 protein, human
  • Cyclic AMP Response Element-Binding Protein
  • HSP90 Heat-Shock Proteins
  • Lactams, Macrocyclic
  • NF-kappa B
  • Proto-Oncogene Proteins c-bcl-2
  • tanespimycin
  • Cytidine
  • pyrimidin-2-one beta-ribofuranoside
  • DNA (Cytosine-5-)-Methyltransferases
  • GSK3B protein, human
  • Glycogen Synthase Kinase 3 beta
  • Cyclic AMP-Dependent Protein Kinases
  • Glycogen Synthase Kinase 3
  • Lithium Chloride
  • Cisplatin
  • Fluorouracil